Clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry Outcome Survey.
Albina NowakJaco BothaChristina AnagnostopoulouDerralynn A Hughes
Published in: Molecular genetics and metabolism (2024)
Continuation and initiation of agalsidase alfa treatment in patients aged 65 years or older with Fabry disease were associated with stabilization of proteinuria and minimal increases in cardiac (LVMI) and renal (eGFR) outcomes.